EA201590193A1 - Препараты лаквинимода без подщелачивающего агента - Google Patents

Препараты лаквинимода без подщелачивающего агента

Info

Publication number
EA201590193A1
EA201590193A1 EA201590193A EA201590193A EA201590193A1 EA 201590193 A1 EA201590193 A1 EA 201590193A1 EA 201590193 A EA201590193 A EA 201590193A EA 201590193 A EA201590193 A EA 201590193A EA 201590193 A1 EA201590193 A1 EA 201590193A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
multiple sclerosis
agent
stable pharmaceutical
subject suffering
Prior art date
Application number
EA201590193A
Other languages
English (en)
Russian (ru)
Inventor
Гади Сарфати
Иоана Ловингер
Данит Лихт
Мухаммад Сафади
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201590193A1 publication Critical patent/EA201590193A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201590193A 2012-07-11 2013-07-10 Препараты лаквинимода без подщелачивающего агента EA201590193A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11
PCT/US2013/049894 WO2014011750A1 (en) 2012-07-11 2013-07-10 Laquinimod formulations without alkalizing agent

Publications (1)

Publication Number Publication Date
EA201590193A1 true EA201590193A1 (ru) 2015-04-30

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590193A EA201590193A1 (ru) 2012-07-11 2013-07-10 Препараты лаквинимода без подщелачивающего агента

Country Status (19)

Country Link
US (1) US20140018386A1 (enExample)
EP (1) EP2872141A4 (enExample)
JP (1) JP2015527321A (enExample)
KR (1) KR20150036553A (enExample)
CN (1) CN104470519A (enExample)
AR (1) AR091706A1 (enExample)
AU (1) AU2013290274A1 (enExample)
BR (1) BR112015000321A2 (enExample)
CA (1) CA2873230A1 (enExample)
EA (1) EA201590193A1 (enExample)
HK (1) HK1209054A1 (enExample)
IL (1) IL236229A0 (enExample)
MX (1) MX2015000398A (enExample)
NZ (1) NZ630241A (enExample)
SG (2) SG11201407688QA (enExample)
TW (1) TW201408299A (enExample)
UA (1) UA115555C2 (enExample)
WO (1) WO2014011750A1 (enExample)
ZA (1) ZA201500287B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
CA2901849A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
EP2687512A1 (en) * 2005-10-19 2014-01-22 Teva Pharmaceutical Industries Ltd. Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof
US7989473B2 (en) * 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
EP2234485B1 (en) * 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
SG10201606204TA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta

Also Published As

Publication number Publication date
JP2015527321A (ja) 2015-09-17
AR091706A1 (es) 2015-02-25
IL236229A0 (en) 2015-01-29
SG11201407688QA (en) 2014-12-30
ZA201500287B (en) 2016-10-26
CN104470519A (zh) 2015-03-25
US20140018386A1 (en) 2014-01-16
KR20150036553A (ko) 2015-04-07
AU2013290274A1 (en) 2014-11-27
EP2872141A1 (en) 2015-05-20
BR112015000321A2 (pt) 2017-06-27
MX2015000398A (es) 2015-04-10
EP2872141A4 (en) 2016-01-13
WO2014011750A1 (en) 2014-01-16
WO2014011750A8 (en) 2014-12-04
SG10201700198VA (en) 2017-02-27
UA115555C2 (uk) 2017-11-27
HK1209054A1 (zh) 2016-03-24
NZ630241A (en) 2017-09-29
TW201408299A (zh) 2014-03-01
CA2873230A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
IN2014DN10386A (enExample)
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12015501609A1 (en) Phenicol antibacterials
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201590191A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и фампридина
IN2014DN09437A (enExample)
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201690673A1 (ru) Комбинированная терапия лахинимодом для лечения рассеянного склероза
MX358072B (es) Composiciones tópicas que comprenden diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que involucran un aumento del dolor.